Drugs / Recombinant Human Chorionic Gonadotrophin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02916173 | Nov 2016 → Oct 2018 | — | Assiut University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00249834 Background | Sep 2004 → Jan 2006 | infertility disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Chorionic Gonadotrophin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02916173 ↗ |
| Known as | r-hCG | “250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.” NCT00249834 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human chorionic gonadotrophin (r-hCG)” NCT00249834 ↗ |
| Route | Intramuscular | “250 unit intramuscular” NCT02916173 ↗ |